Company Shown To Have Concealed Falsified Study Results In Stock Drop Suit

Mealey's (March 22, 2018, 1:28 PM EDT) -- NEW YORK — An Israeli clinical stage biopharmaceutical company that develops combination drugs for the treatment of osteoarthritis and hypertension issued material misrepresentations and omissions concealing that the company’s CEO falsified clinical study results for the development of its lead drug candidate in violation of federal securities law, a federal judge in New York ruled March 20 in granting in part and denying in part the defendants’ motion to dismiss (Rotem Cohen, et al. v. Kitov Pharmaceuticals Holdings Ltd., et al., No. 17-0917, S.D. N.Y., 2018 U.S. Dist. LEXIS 45676)....